ILS-920

产品说明

一般描述

Synonym: (3S,6R,7E,9R,10R,12R,14S,15S,18R,19E,21S,23S,26R,27R,34aS)-3,4,9,10,13,14,15,16,18,21,22,23,24,25,26,27,32,33,34,34a-eicosahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-16-phenyl-23,27-epoxy-15,18-ethenopyrido[2,1-r][1,16,2,19]dioxadiazacyclohentriacontine-1,5,11,28,29(6H,12H,31H)-pentone

包装

5, 25 mg in glass bottle

生化/生理作用

ILS-920 is a rapamycin derivative with reduced immunosuppressive activity and enhanced neuroprotective activities including efficacy in vivo stroke model. ILS-920 predominantly binds to FKBP52 with a 972-fold higher selectivity for FKBP52 vs. FKBP12 than that of rapamycin, and also binds to the β-subunit of L-type voltage dependent Ca²⁺ channels. This dual functionality may contribute to the compound′s efficacy in stroke models.

其他说明

This compound was developed by Pfizer for Immunology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

法律信息

Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.

基本信息

产品性质

安全信息